Adjuvant lapatinib and trastuzumab for early human epidermal growth factor receptor 2-positive breast cancer: Results From the randomized phase III adjuvant lapatinib and/or trastuzumab treatment optimization trial.
Journal of Clinical Oncology.
Times cited: 65
Correction: Folate receptor-α (FOLR1) expression and function in triple negative tumors.
Times cited: 5
RC0639: Phase II study of paclitaxel, trastuzumab, and lapatinib as adjuvant therapy for early stage HER2-positive breast cancer.
Breast Cancer Research and Treatment.
Times cited: 12